북미 약물-장치 조합 시장 – 2028년까지의 산업 동향 및 예측

시장 분석 및 통찰력 : 북미 약물-장치 조합 시장

약물-장치 조합 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 10.9%의 CAGR로 성장하고 있으며 2020년의 8,086.79백만 달러에서 2028년까지 17,843.53백만 달러에 도달할 것으로 예상된다고 분석했습니다. 약물-장치 조합 제품 사용 증가, COVID-19 발생률 증가는 예측 기간 동안 시장 수요를 촉진한 주요 요인입니다.

만성 질환의 증가된 유행은 기술 발전으로 약물-장치 조합 시장의 성장에 효과적으로 도움이 됩니다. 그러나 약물-장치 조합과 관련된 한계와 합병증은 의료 기기 시장의 미래 발전을 방해할 수 있습니다. 주요 시장 참여자의 파트너십과 협력은 글로벌 약물-장치 조합 시장의 성장을 위한 기회로 작용합니다.

약물-장치 조합 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.

북미 약물-장치 조합 시장 범위 및 시장 규모

약물-장치 조합 시장은 제품, 응용 프로그램, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.

• On the basis of product, the drug-device combination market is segmented into auto-injector, microneedle patch, digital pill, smart inhaler, drug delivery hydrogels, drug-eluting lens, and others. Auto-injector is further sub-segmented into wearable auto-injector, hand-held auto-injector. In 2021, auto-injector holds highest share in the drug-device combination market as large number of patient pool suffering from chronic diseases.
• On the basis of application, the global drug-device combination market is segmented into orthopedic diseases, respiratory diseases, diabetes, oncology, cardiovascular diseases, and others. In 2021, the orthopedic is expected to dominate the drug-device combination market due to the growing number of surgeries. Moreover, an initiative by the government anticipated propelling the further market growth.
• On the basis of end users, the drug-device combination market is segmented into clinics, hospitals, home care settings, ambulatory care centers, and others. In 2021, the clinics are expected to dominate the drug-device combination market because most patients are suffering from chronic diseases, so they would be seen in the clinics to get proper regular check-ups, treatment and management. Moreover, due to COVID-19, most patients do not prefer to visit hospitals in fear of infection.
• On the basis of distribution channel, the drug-device combination market is segmented into direct tender, retail sales, and others. In 2021, the direct tender is expected to dominate the drug-device combination market due to having complete control over the sales and revenue process as well as direct interaction with your customers. The segment is growing due to increasing number of hospitals in developed as well as developing  countries.

Drug-Device Combination Market Country Level Analysis

The drug-device combination market is analysed, and market size information is provided by product, application type, end user, and distribution channel. The countries covered in the drug-device combination market report are the U.S., Canada, and Mexico.  

North America is expected to dominate the market due to the high adoption of drug-device combination products by the patients in the region. U.S is dominating in the market and leading the growth in the North America market due to increased presence of key market players in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Increasing Collaborations and Partnerships in Drug-Device Combination Market is Creating New Opportunities for Players in the Drug-Device Combination Market  

Drug-Device combination market also provides you with detailed market analysis for every country growth. Additionally, it provides data regarding collaborations and partnerships among the major market plyers and start-up companies. Moreover, the growing impact of research and development activities on drug-device combination market growth pace. The data is available for historic period 2010 to 2019

Competitive Landscape and   Medical devices Market Share Analysis

Drug-Device combination market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to drug-device combination market.

The major players covered in the report Mediprint, OcuMedic, Medtronic, GlaxoSmithKline Plc, BD, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Bayer AG, Micron Biomedical, Inc., Otsuka America Pharmaceutical, Inc., VAXXAS, Propeller Health, Raphas Co., Ltd., EOFLOW CO., LTD., Insulet Corporation, TheraJect, Zimmer Biomet, Amgen Inc., Eitan Medical among others domestic and North America players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Growing Collaboration, contract and agreement by key players accelerating the market growth.

For instance,

• In March 2021, Eitan Medical collaborated with Stevanato for bringing wearable injection solutions to market for the simple and efficient subcutaneous administration of large-volume and high viscosity medications that serve the interests of both patients and pharmaceutical companies. This would strengthen leadership and innovation capabilities globally.
• 4월, EOFlow Co., Ltd.의 미국 자회사 Nephria는 Drexel University로부터 새로운 "MXene" 나노소재에 대한 라이선스를 취득했습니다. Nephria는 독점권을 취득했으며 이 기술 이전을 시작으로 착용형 투석 시스템, 즉 착용형 인공 신장(WAK)을 개발할 계획이었습니다. 이를 통해 새로운 치료 분야의 기술이 가속화되고 시장 성장이 증가할 것입니다.
• 2020년 1월, Amgen Inc.는 BeiGene과의 성공적인 전략적 협력을 발표했습니다. 이 협력은 향후 몇 년 동안 중국 종양학 시장에서 회사의 입지를 강화할 것으로 예상됩니다.

시장 참여자의 파트너십, 합작투자 및 기타 전략은 약물-의료기기 조합 시장 성장을 촉진하고 있으며, 이는 기업이 더 나은 고객 경험을 위해 제공 서비스를 개선하는 데에도 도움이 됩니다.

SKU-65747